Current knowledge on Alzheimer's disease

Neurologia Croatica

Volumn 46, Issue 3-4, 1997, Pages 55-72

  Babic T ^b   Smith, R J ^a   Petravic D ^b  

^a Memory Assessment Clinics Ltd   (United Kingdom)

^b KBC Zagreb   (Croatia)

Author keywords

Alzheimer's dementia; Apo E4; Cholinesterase inhibitors

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TAU PROTEIN; UNCLASSIFIED DRUG;

AGING; ALLELE; ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; HUMAN; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 0031462597     PISSN: 03538842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. th ed. New York: McGraw-Hill Book Comp., 1997.
2. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Ztschr Psychiat 1907; 64: 146-148.
3. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal antinflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995; 45: 1441-1445.
4. Arendt T, Schindler C, Bruckner MK et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein 4 allele. J Neurosci 1997; 17: 516-529.
5. Berrios GE, Freeman HL. Alzheimer and Dementias. London: Royal Society Medical Service, 1991.
6. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
7. Breteler MMB, Claus JJ, van Dujin CM et al. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992; 14: 59-82.
8. th ed. New York: McGraw-Hill Book Comp. 1954; I: 137-146.
9. Burns A, Philpot MP, Costa DC, Ell PJ, Levy R. The investigation of Alzheimer's disease with single photon emission tomography. J Neurol Neurosurg Psychiatry 1989; 52: 248-253.
10. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoproteine E type allele and the risk of Alzheimer's disease in late onset families. Science 1993; 3: 569-574.
11. Coreybloom J, Galasko D, Hofstetter CR et. al. Clinical features distinguishing large cohorts with possible AD, probable AD and mixed dementia. J Am Geriatr Soc 1993; 41: 31-37.
12. Cozantis D, Dessypris A, Nuutila K. The effect of galanthamine hydrobromide on plasma ACTH in patients undergoing anaesthesia and surgery. Acta Anaesthesiol Scand 1980; 28: 166-168.
13. Cummings JL, Benson DF. Facts about Alzheimer's disease. A practitioner's guide. The French Foundation of Alzheimer's Research, 1994:3-2
14. th ed. Washington DC: American Psychiatric Association, 1994.
15. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older person. JAMA 1989; 262: 2551-2556.
16. Folstein M, Folstein S, McHugh P. Mini-mental state. A practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
17. Goate A, Chartier-Harlin M-C, Mullen M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
18. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer's paired helical filaments - abnormal phosphorylation of all 6 brain isoforms. Neuron 1992; 8: 159-168.
19. Hardy JA, Higging GA. Alzheimer's disease - the amyloid cascade hypothesis. Science 1992; 256: 184-185.
20. Hasenbroekx C, Lebert F, Pasquier F, Petit H. Convulsive effect of tacrine. Fourth International Nice/Springfield Symposium on Advances in Alzheimer's Therapy. Nice, 1996.
21. Henderson AS. Epidemiology of mental disorders and psychosocial problems: dementia. Geneva: WHO, 1994.
22. Henderson JM, Hubbard BM. Definition of Alzheimer disease. Lancet 1985; 1: 408-410.
23. Herholtz K, Adams R, Kessler R et al. Criteria for diagnosis of Alzheimer's disease with positron emission tomography. Dementia 1990; 1: 156-164.
24. Hofman A, Rocca WA, Brayne C et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 1991; 20: 736-748.
25. Leber P. Guidelines for the clinical evaluation of antidementia drugs. Rockville, MD: Food and Drug Administration, Centre for Drug Evaluation and Research, Office of Drug Evaluation, Division of Neuropharmacologic Products, Draft dated November 8, 1990.
26. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994; 13: 131-144.
27. Levy-Lahad E. Wijsman EM, Nemens E et al. A familial Alzheimer's disease locus on chromosome 1. Science 1995; 269: 970-972.
28. McKahn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
29. Mesliah E, Mallory M, Ge NF, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 1995; 136: 107-122.
30. Mirra SS, Heyman A, McKeel D et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 2. Standardisation of the neuropathologic assessment of Alzheimer's Disease. Neurology 1991; 41: 479-486.
31. Morris JC. Clinical and Neuropathological Findings from CERAD. Fourth International Nice/Springfield Symposium on Advances in Alzheimer's Therapy. Nice: 1996.
32. Nathan BP, Chang KC, Bellosta S et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. Biol Chem 1995; 270: 1971-19799.
33. Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer MM, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res 1987; 28: 271-380.
34. Perry EK, Thomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457-9.
35. Poirier J, Davignon J, Bouthilier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697-699.
36. Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl Acad Sci USA 1995; 92: 12260-12264.
37. Polvikoski T, Sulkava R, Haltia M et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995; 333: 1242-1247.
38. Recognition and initial assessment of Alzheimer's disease and related dementias. Clinical practice guideline No 19. Rockville, MD: Agency for Health Care Policy and Research, US Department of Health and Human Services. AHCPR Publication No 96-0702, September 1996.
39. Richie K, Kildea D, Robine JM. The relationship between age and the prevalence of senile dementia: a meta-analysis of recent data. Int J Epidemiol 1992; 21: 763-769.
40. Ritchie K, Kildea D. Is senile dementia "age-related" or "ageing-related"? - evidence from metaanalysis of dementia prevalence in the oldest old. Lancet 1995; 346: 931-934.
41. Rocca W. Epidemiologia de las demencias vasculares y degenerativas en los EE UU y Europa. Ist Reunion Conjunta Grupos de Investigacion en Demencias. Federacion Mundial De Neurologia y Sociedad Neurogica Argentina. Buenos Aires, 1996.
42. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 23-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
43. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 14: 1356-1364.
44. nd ed. Boston: Butterworth-Heinemann, 1995; II: 1586-1599.
45. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
46. Schellenberg GD, Bird TD, Wijsman EM et al. Genetic linkage evidence for familial Alzheimer's disease locus on chromosome 14. Science 1992; 258: 668-671.
47. Schmechel DE, Saunders AM, Strittmatter WJ et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late onset of Alzheimer's disease. Proc. Natl Acad Sci USA 1993; 90: 9649-9653.
48. Schoenberg BS, Kokmen E, Okazaki H. Alzheimer's disease and other dementing illnesses in a defined United States population: incidence rates and clinical features. Ann Neurol 1987; 22: 724-726.
49. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein (review). Annu Rev Neurosci 1994; 17: 489-517.
50. Small GW, Mazziotta JC, Collins MT et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer's disease. JAMA 1995; 273: 942-947.
51. Snorrason E, Geirsson A, Stefansson K. Trial of a selective acetylcholinesterase inhibitor, galanthamine hydrobromide, in the treatment of chronic fatigue syndrome. J Chron Fatigue Sy 1996; 2: 35-54.
52. Soininen H, Kosunen O, Helisalmi S et al. A severe loss of choline acetyltransferase in the frontal cortex of.Alzheimer's patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett 1995; 187: 79-82.
53. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981.
54. rd Ed. Philadelphia, PA: F.A. Davis Company, 1993.
55. Tang M-X, Jacobs D, Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-430.
56. Terry RD, Masliah E, Salmon DP et al. Physical basis of cognitive alteration in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
57. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galantamine in vitro and in vivo. Life Sci 1990; 46: 155-1558.
58. Whitehouse P, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer's disease and senile dementia: loss of neurones in basal forebrain. Science 1982; 215: 1237-1239.
59. Whitehouse P. Diagnosis of Alzheimer's disease. Ist Reunion Conjunta Grupos de Investigacion en Demencias. Federacion Mundial De Neurologia y Sociedad Neurologica Argentina. Buenos Aires, 1996.
60. Wilcock GK, Wilkinson D. Galantamine hydrobromide - interim results of a group comparative, placebo controlled study of efficacy and safety in patients with diagnosis of senile dementia of the Alzheimer's type. Fourth International Congress on Alzheimer's Disease and related Disorders, Osaka, July 1996.
61. Wimo A, Mattsson B, Krakau I et al. Cost-effectiveness analysis of dementia day care - controlled Swedish study. Health Economics 1994; 3: 395-404.